The rapidly increasing use of pegasparaginase (pegASNase) in adults, after a half century
of use of asparaginase (ASNase) in children, has prompted a need for guidelines in the …

Objective A current assessment of case reports of possible drug-induced pancreatitis is
needed. We systematically reviewed the case report literature to identify drugs with potential …

Summary l‐asparaginase has been an element in the treatment for acute lymphoblastic
leukaemia (ALL) and non‐H odgkin lymphoma since the late 1960s and remains an …

Abstract L-asparaginase (L-ASNase) has been an essential component of multiagent
chemotherapy for acute lymphoblastic leukemia in childhood for over 3 decades. There are …

Background Pancreatitis is a well‐known, but little‐understood complication of
asparaginase. There is no predictor of who will develop asparaginase‐associated …

The incorporation of L-asparaginase and pegylated asparaginase into pediatric-inspired
regimens has conferred a survival advantage in treatment of adults with acute lymphoblastic …

Background L-asparaginase (L-asp) is used as part of the initial treatment in children with
acute lymphoblastic leukemia (ALL), inducing remission in 83% to 95% of the treated …

Little is known about octreotide therapy in asparaginase‐associated pancreatitis (AAP) in
children. Of the 59 children with acute lymphoblastic leukemia (ALL) receiving E. coli l …

Octreotide is a somatostatin analogue that has been suggested as a therapeutic agent in
various diverse disease processes including gastrointestinal bleeding, pancreatitis …

Introduction he most common cause of early treatment failure among patients with childhood
leukemia is death from the acute complications of the leukemia itself or its initial treatment. 1 …